Centessa Pharmaceuticals plc is a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients. Centessa Pharmaceuticals plc is based in Cambridge, United Kingdom.
| Revenue (Most Recent Fiscal Year) | $6.85M |
| Net Income (Most Recent Fiscal Year) | $-235.76M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 12.91 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1595.38% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -49.39% |
| Return on Assets (Trailing 12 Months) | -34.64% |
| Current Ratio (Most Recent Fiscal Quarter) | 10.56 |
| Quick Ratio (Most Recent Fiscal Quarter) | 10.57 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.36 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.05 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.41 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.49 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.83 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 134.42M |
| Free Float | 124.89M |
| Market Capitalization | $3.91B |
| Average Volume (Last 20 Days) | 2.11M |
| Beta (Past 60 Months) | 1.55 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.09% |
| Percentage Held By Institutions (Latest 13F Reports) | 82.01% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |